Sanofi sales and marketing update

Sanofi’s Genzyme Corp. launched Lemtrada alemtuzumab in the U.S. to treat relapsing forms of multiple sclerosis (MS). The wholesale acquisition cost (WAC) for 1.2 mL of 10 mg/mL solution is $19,750....